2. Academic Validation
  3. Recent progress in LyP-1-based strategies for targeted imaging and therapy

Recent progress in LyP-1-based strategies for targeted imaging and therapy

  • Drug Deliv. 2019 Dec;26(1):363-375. doi: 10.1080/10717544.2019.1587047.
Ningning Song 1,  Lingzhou Zhao 1,  Meilin Zhu 2,  Jinhua Zhao 1
Affiliations

Affiliations

  • 1 a Department of Nuclear Medicine , Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , People's Republic of China.
  • 2 b School of Basic Medical Sciences, Ningxia Medical University , Yinchuan , People's Republic of China.
PMID: 30905205 DOI: 10.1080/10717544.2019.1587047
Abstract

The identification of markers expressed by pathological cells or their microenvironment would help to distinguish such cells from the normal tissues. The strategies derived from this theory can be a promising modality for imaging and treating diseases. LyP-1, a tumor homing peptide, can selectively bind to its receptor p32 protein overexpressed in various tumor-associated cells and atherosclerotic plaque macrophages. During recent decades, multiple types of LyP-1-based imaging probes and drug delivery systems have been designed and developed for diagnostic and therapeutic applications. This review first introduces LyP-1 and its receptor p32, as well as its homing, internalization and proapoptotic properties. Next, we highlight recent studies focusing on the applications of LyP-1-based strategies in the diagnosis and treatment of tumors, metastatic lesions, and atherosclerotic plaques. Finally, several limitations in the clinical translation of LyP-1-based bioconjugates are summarized.

Keywords

LyP-1; atherosclerotic plaque; diagnosis and therapeutics; metastatic lesions; tumor.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P2526A
    99.87%, LyP-1 (8 weeks) shows a remarkable reduction in plaque formation and plaque occupation rates in the LyP-1-treated group. In addition, a higher apoptotic rate in macrophages released from hypoxic plaques is observed after the treatment of LyP-1when compared to control peptide[1].
    The LyP-1 peptide is labeled with a near-infrared fluorophore (Cy5.5) for optical imaging.
    At days 3, 7, 14 and 21 after inoculation with 4T1 cells, tumor-bearing BALB/C mice is injected Cy5.5-LyP-1 (0.8 nmol) through the middle phalanges of the upper extremities of the tumor-bearing mice. The fluorescence intensities were 0.024, 0.038, 0.048 and 0.106×106 photon/cm2/sec respectively at days 3, 7, 14 and 21 after tumor cell inoculation, which are 1.02, 1.63, 2.04, and 4.52-fold higher than in the contralateral LNs. Cy5.5-LyP-1 staining in LNs co-localized with LYVE-1, suggesting lymphatics-specific binding of LyP-1 peptide[1].
  • HY-P2526
    Tumor Homing Peptide